Authors:
Address: Department of Physiology and Pharmacology, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, NY 10031, United States.
Journal:

Publication:

abstract

The balance between phase-I carcinogen-activating and phase-II detoxifying xenobiotic metabolizing enzymes is critical to determining an individual's risk for cancer. We evaluated the effect of Hydrogen sulfide-releasing aspirin (HS-ASA) on xenobiotic metabolizing enzymes in HT-29 human colon and Hepa 1c1c7 mouse liver adenocarcinoma cells and in Wistar rats. HS-ASA inhibited the growth of HT-29 and Hepa 1c1c7 cells, with an IC(50) of 3.2 ± 0.3 μM and 4.2 ± 0.4 μM, respectively. The IC(50) for ASA in both cell lines was greater than 5000 μM at 24h. In these cell lines, HS-ASA caused a dose-dependent increase in activity and expression of the phase-II enzymes glutathione S-transferase (GST) and NAD(P)H:quinoneoxireductase (NQO1). It also caused an increase in UDP-glucuronosyltransferase (UGT) expression. The levels of CYP 1A1 a phase-I enzyme was increased by HS-ASA in both cell lines. Pretreatment of cells with NaF, an esterase inhibitor, abrogated the HS-ASA-mediated increases in NQO1 enzyme activity. HS-ASA increased the protein levels of the transcription factor Nrf2, which is a regulator of the phase-II enzymes. In vivo, HS-ASA at 100mg/kg/day had no effect on rat's weights; it induced a 3.4-fold and 1.4-fold increase in hepatic GST and NQO1 enzyme activities, respectively. GST and NQO1 protein levels were also increased. In contrast to that in cultured cells, CYP 1A1 protein levels were not altered in vivo. Therefore, HS-ASA induces phase-II enzymes, at least in part, through the action of H(2)S and by modulating Nrf2; these effects may be part of its mechanism of action against carcinogenesis.

Copyright © 2011 Elsevier Inc. All rights reserved.

Related Articles
NO-donating aspirin induces phase II enzymes in vitro and in vivo.
Carcinogenesis. 2006
NO-donating aspirin induces phase II enzymes in vitro and in vivo.
Gao J, Kashfi K, Liu X, Rigas B. Carcinogenesis. 2006 Apr; 27(4):803-10. Epub 2005 Nov 2.
Transcriptional regulation of the NAD(P)H:quinone oxidoreductase 1 and glutathione S-transferase ya genes by mercury, lead, and copper.
Drug Metab Dispos. 2006
Transcriptional regulation of the NAD(P)H:quinone oxidoreductase 1 and glutathione S-transferase ya genes by mercury, lead, and copper.
Korashy HM, El-Kadi AO. Drug Metab Dispos. 2006 Jan; 34(1):152-65. Epub 2005 Oct 21.
Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Biochem Pharmacol. 2012
Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. Biochem Pharmacol. 2012 Mar 15; 83(6):723-32. Epub 2011 Dec 24.
Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione.
Mol Med. 2001
Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione.
Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW. Mol Med. 2001 Feb; 7(2):135-45.
Review Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.
Toxicol In Vitro. 2006
Review Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.
Moon YJ, Wang X, Morris ME. Toxicol In Vitro. 2006 Mar; 20(2):187-210. Epub 2005 Nov 11.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster